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The phenomenon by which tumor-bearing hosts are capa-
ble of inhibiting secondary tumor implants or metastases,
known as concomitant antitumoral resistance (CAR), is pre-
sumably due to antiangiogenesis at places distant from the
primary tumor. Although angiostatin, a potent inhibitor of
angiogenesis, has been reported to be one of the factors
responsible for suppressing the growth of secondary tumors
in mice bearing previous tumors, it has not been definitively
proven yet. With the aim of investigating whether CAR-
inducing cancer cells display a differential angiostatin produc-
tion and to support the role ascribed to that molecule con-
cerning the inhibition of secondary tumor implants, 5 tumor
models with different CAR-inducing capacities were studied
herein. One of the 2 human lung cancer cell lines analyzed
revealed a strong CAR against secondary s.c. tumor implants
in nude mice, and 2 of 3 of the murine mammary tumors
used exhibited inhibitory effect on secondary s.c. and i.v.
tumor inoculations in syngeneic hosts. Since angiostatin is a
proteolytic fragment from plasminogen, we examined by
Western blot the ability of all conditioned media collected
from the tumor cells studied to convert plasminogen to
angiostatin. An association between in vivo generation of
CAR and in vitro conversion of plasminogen into angiostatin
was found. Since different enzymatic mechanisms were de-
scribed to explain the generation of angiostatin, we also
studied gelatinase and urokinase-type plasminogen activator
secretion in conditioned media by zymography. The conver-
sion of plasminogen into angiostatin by conditioned media
was mainly inhibited by broad-spectrum serine proteinase
inhibitors, suggesting a possible role for 1 or more enzymes
of that group in the process. These findings suggest the
existence of a differential angiostatin generation by CAR-
inducing cancer cells, providing additional support to previ-
ous data obtained by other authors.
© 2002 Wiley-Liss, Inc.
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Based on clinical observations, at least 4 common patterns of
metastases are observed in cancer patients, namely that of (i) rapid
growth of metastases after surgical extirpation of a primary tumor;
(ii) presence of metastases at the time of primary tumor diagnosis;
(iii) metastases with occult primary tumor; and (iv) appearance of
metastases many years after removal of the primary tumor.1 The
first of the cases mentioned above, observed not only in clinical2–5
but also in experimental6–12 situations, suggests that some primary
tumors are capable of inhibiting the growth of secondary tumors or
metastases. This phenomenon was described at the beginning of
20th century by Ehrlich13 and was designated as concomitant
immunity by Bashford,14 assuming that it could be explained by
immunologic means. Many years passed by until the phenomenon
could also be recognized with tumors of nondetectable immuno-
genicity or in immunodeficient mice,6,7 and the term CAR3 was
proposed.8 The paradoxical inhibitory effect exerted by some
primary neoplasms on the growth of secondary tumors at distant
places is also observed on metastasis development. In fact, we
observed an inverse correlation between metastatic capacity and
CAR.9
Angiogenesis, the formation of new blood vessels from the
existing vascular bed, is pivotal to primary tumor growth and
metastasis. Folkman’s pioneering work introduced the concept that
all solid tumors depend on angiogenesis to grow.15,16 The corrob-
oration of his hypothesis is well supported by several investiga-
tions and opened new avenues for novel therapeutic strategies
based on the use of antiangiogenic factors. One of the main
advantages of this type of treatment is supported by the assumption
that they would not generate resistance mechanisms, due to the
genetic stability of endothelial cells.17–19 Some of the antiangio-
genic factors are secreted in their active form, such as throm-
bospondin,19 whereas others are converted into antiangiogenic by
proteolytic action on inactive extracellular molecules, as is the case
of angiostatin and endostatin.10,20
Since others and we have previously observed that antiangio-
genesis and apoptosis could act as mediators of CAR,10,21–23 it is
of great importance to study the role of different natural inhibitors
of angiogenesis in such phenomenon.
Angiostatin, an internal fragment of plasminogen including
kringles 1–4, is a potent angiogenesis inhibitor that has been found
in the circulation of tumor-bearing mice, which disappears after
surgical tumor removal.10 Although the mechanisms by which it is
generated in vivo remain unknown, different authors have shown
that angiostatin can be generated in vitro by the proteolytic cleav-
age of plasminogen by different serine-, metallo- and aspartic
proteases secreted by tumor cells themselves or tumor-infiltrating
macrophages.24–31
Here, we studied the ability of 3 murine mammary adenocarci-
nomas and 2 human lung cancer cell lines to produce angiostatin,
in relation to their capacity to induce CAR. An association be-
tween both phenomena, as well as the involvement of serine
proteinases in the generation of the angiostatic factor, was found.
MATERIAL AND METHODS
Cell culture
Human lung cancer-derived cell lines Calu-6 and H460, ob-
tained from ATCC (Rockville, MD), and M3MC, M234p and
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M234m, mammary adenocarcinomas spontaneously arisen in
BALB/c mice, were used throughout. Tumor cells were cultured in
RPMI-1640 medium (Sigma, St. Louis, MO) supplemented with
10% FBS (Gen, Buenos Aires, Argentina), except for M234m that
used MEM medium (Sigma) with 20% FBS. CMs were generated
by 48 hr exposure of confluent monolayers to their respective
FBS-free media.
Concomitant antitumoral resistance assay
Three-month-old N:NIH (S) nude mice (Animal Care Facilities
of the School of Veterinary Medicine, University of La Plata, La
Plata, Argentina) were inoculated s.c. in their left flanks with 2 
106 Calu-6 or H460 cells, as previously reported.21 In the case of
M3MC, M234p and M234m, 1  106 cells were inoculated s.c. in
3-month-old female BALB/c mice (Animal Care Facilities of the
School of Veterinary Medicine, University of La Plata and School
of Medical Sciences, University of Rosario, Rosario, Argentina).
When tumors grew to a median volume of 600 mm3, a secondary
inoculation of the respective cell type at the same initial dose was
carried out in the right flank. The phenomenon of CAR was
evidenced as delayed, lower or no growth of the secondary tumor,
with respect to control mice (with no previous tumor inoculation in
left flank). Percentage of secondary TVI was calculated as (1 
E/C)  100, where E is the median volume of secondary tumors
in tumor-bearing mice and C is that of control mice injected with
tumor cells in the second instance. Other experiments in which the
nonspecificity of CAR was analyzed were performed as above,
except that the tumor cells of the secondary inoculum were dif-
ferent from those of the primary one. The assay for CAR against
experimental metastases was carried out with M3MC and M234p.
In that case, the secondary tumor inoculation was carried out i.v.
with 4 104 and 106 cells, respectively. The number of metastatic
nodules observed in lungs 21 days later was used to evaluate the
CAR generation. Metastasis inhibition was calculated in a similar
way to TVI, except that E represents the number of lung nodules
in tumor-bearing mice and C that of control mice. The animals
were subjected to a 12 hr light/12 hr dark cycle and maintained on
pellets and water ad libitum. Nude mice were housed in sterile
polycarbonate cages with microbarrier tops (Nalge, Rochester,
NY) and maintained in aseptic conditions inside animal storage
cabinets with sterile air laminar flow and controlled environment
(Flufrance, Wissous, France).
Angiostatin detection
Sera obtained from mice bearing tumors derived from each one
of the cancer cells under study were purified with lysine-sepharose
(Pharmacia, Uppsala, Sweden). Briefly, 200 l of each serum were
added to 50 l lysine-sepharose slurry, incubated on a roller bank
for 60 min at room temperature and finally eluted with 50 l of 0.2
M -amino-caproic acid.32 Purified samples were analyzed for
angiostatin by Western blot using a rabbit antibody raised against
a synthetic peptide whose sequence is derived from the amino
terminus (residues 1–19) of mouse angiostatin protein (Affinity
Bioreagents, Golden, CO). Briefly, samples were subjected to
SDS-PAGE under reducing conditions and then electrotransferred
to 0.45 nitrocelullose membrane (Bio-Rad, Hercules, CA). After
blocking the membrane for 30 min (2% skim milk in TBS, pH 7.5),
it was probed with the rabbit antibody to angiostatin (8 g/ml) for
1 hr at room temperature. This antibody does not work under
nonreducing conditions. The membrane was washed, then incu-
bated for 30 min with a 1:60,000 dilution of a peroxidase-conju-
gated goat anti-rabbit IgG secondary antibody (Sigma) and finally
developed using an enhanced chemiluminescence kit (Amersham,
Piscataway, NJ) and exposed to X-ray film.
To investigate the in vitro generation of angiostatin, 100 l of
cell-number-standardized samples of the different CMs were in-
cubated with 2.8 g of human plasminogen (Sigma) for 48 hr at
37°C. Control groups consisted of FBS-free culture media instead
of CMs. Aprotinin (100 M), leupeptin (5 M), soybean trypsin
inhibitor (100 g/ml), EDTA.Na2 (5 mM) (all purchased from
Sigma), TIMP-1 and TIMP-2 (Calbiochem, San Diego, CA) at
concentrations 0.01–1 g/ml, 2-antiplasmin (Sigma) 0.01–10
g/ml and neutralizing antibody against uPA (American Diagnos-
tica, Bethesda, MD), 0.01–10 g/ml, were used for enzyme inhi-
bition studies. In all cases the inhibitors were incubated with CMs
for 1 hr at 37°C before exposure to plasminogen. Aliquots were
withdrawn from the reaction mixture, subjected to nonreducing
SDS-PAGE and transferred to nitrocellulose. Detection of plas-
minogen conversion was evidenced by Western blot analysis using
a 1:1,000 dilution of a monoclonal antibody specific for kringles
1–3 domains of human plasminogen (VAP 250L; Enzyme Re-
search Laboratories, South Bend, IN). To visualize binding of the
first antibody, a rabbit anti-mouse Fc secondary antibody conju-
gated to alkaline phosphatase (1:10,000) and nitroblue tetrazolium
as substrate were used. In all cases, commercially available human
angiostatin (Angiogenesis Research Industries, Chicago, IL) was
run as a positive control.
Zymographic analysis
Gelatinase (MMP-2 and MMP-9) and uPA activities were ana-
lyzed in CMs by standard techniques using 7.5% and 11% SDS-
PAGE with gelatin or casein/plasminogen, respectively.33
FIGURE 1 – Concomitant antitumoral resistance induced by Calu-6
(a) and H460 (b) human lung cancer cell lines in nude mice. Median
tumor volume in right flank vs. time is shown: , mice with primary
tumor grown in left flank; F, control mice without previous tumor.
Experiments were conducted as described in Material and Methods.
Dimensions of tumors in right flank (2nd tumors) were calculated at
the indicated intervals according to the equation V  0.4 (ab2), where
V  volume, a  largest diameter and b smallest diameter. The data
shown represent the median values (n  5). p according to Mann-
Whitney U-test: **  0.01.
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Statistical analysis
The nonparametric Mann-Whitney U-test was performed on
data employing the statistical software package GraphPad In
Stat™. Differences were considered significant when p  0.05.
RESULTS
Concomitant antitumoral resistance
To study the capacity of the neoplastic cells here used to
induce CAR, mice bearing 600 mm3 median volume s.c. tumors
were contralaterally s.c. challenged with the same tumor cells.
Controls consisted of mice that only received the latter tumor
inoculation. CAR was evidenced as delayed, lower or no growth
of the secondary tumor with respect to control mice. As for
human lung cancer cell lines transplanted in nude mice, Calu-6
revealed a strong CAR (Fig. 1a), while H460 did not (Fig. 1b).
The results obtained with Calu-6 confirmed those previously
reported.21 With respect to BALB/c mouse mammary tumors
studied, M3MC and M234p exhibited a very strong inhibition
of secondary tumor implants (Fig. 2a,b, respectively). TVI for
M3MC varied from 95.49 –96.53% between 15–30 days after
secondary tumor inoculation. In the case of M234p, TVI was
100% from day 18 on, since median secondary tumor volume in
tumor-bearing mice was 0. In the experimental group, only 1/6
of M234p tumor-bearing mice developed a secondary tumor
growth, while 6/6 of the tumor implants carried out at the same
time in control mice grew. On the contrary, M234m exhibited
no differences in the growth of tumor implants carried out in the
second instance (Fig. 2c).
The nonspecificity of CAR was assayed in mice bearing CAR-
inducing tumors secondarily challenged s.c. with those tumor cell
types that did not induce the phenomenon. As shown in Table I,
the human lung cancer cell line Calu-6 was able to inhibit in a
significant way the growth of secondary contralateral implants of
H460 carried out in nude mice. Similarly, M234p induced CAR
against M234m in BALB/c mice (Table I). Previous results dem-
onstrated the ability of M3 primary tumors to exert CAR against
i.v. inocula of the metastatic MM3 tumor cells, inhibiting signif-
icantly the number of lung metastases in mice with respect to
control mice with no primary tumor.9
Concomitant antimetastatic resistance
To verify whether the capacity to induce CAR against s.c.
secondary implants is also effective against experimental lung
metastases, M3MC and M234p were i.v. inoculated in tumor-
bearing and control naive mice. The presence of s.c. primary
tumors in both models markedly reduced the outgrowth of lung
metastatic nodules (Fig. 3), revealing metastasis inhibitions of
83% and 98.65% for M3MC and M234p, respectively.
Analysis of angiostatin in tumor sera and conditioned media
The presence of angiostatin in sera from tumor-bearing mice
was investigated by Western blot, as described in Material and
Methods. The angiogenesis inhibitor protein was not detected in
either case, although plasminogen was observed in all sera (data
not shown). As an alternative, we analyzed the in vitro capacity of
tumor cells to generate angiostatin from plasminogen. Conditioned
media obtained from Calu-6, M3MC and M234p, the tumor cells
that manifested the capacity of generating in vivo CAR, were able
to convert plasminogen into angiostatin (Fig. 4). This molecule is
usually detected as a doublet at approximately 50 kDa, as con-
firmed by the human angiostatin run as a control. A band corre-
sponding to the approximately 65 kDa heavy chain of plasmin was
also detected in all the cases. As a consequence of the enzymatic
conversion into plasmin and angiostatin, a decrease in density of
plasminogen band at approximately 92 kDa was observed (Fig. 4).
FIGURE 2 – Concomitant antitumoral resistance induced by M3MC (a), M234p (b) and M234m (c) murine mammary tumor cells in BALB/c
mice. Median tumor volume in right flank (2nd inoculum) vs. time is shown: , mice with primary tumor grown in left flank; F, control mice
without previous tumor. Experiments were conducted as described in Material and Methods. Tumor dimensions were calculated as indicated in
the legend for Figure 1. The data shown represent the median values (n  5–6). p according to Mann-Whitney U-test: *  0.02, **  0.01.
TABLE I – IN VIVO INHIBITORY EFFECT OF CAR-INDUCING PRIMARY
TUMORS ON CONTRALATERAL IMPLANTS OF NONINDUCING
CAR TUMOR CELLS1
Primary tumor
inoculum
Contralateral tumor
inoculum
Tumor volume of contralateral
tumor2 (median [range], mm3) TVI
3
Calu-6 H460 28.4 [0–50]** 94.7
None
(control)
H460 538.5 [324–680]
M234p M234m 47.8 [0–101]* 81.9
None
(control)
M234m 263.6 [48–454]
1Primary tumors were generated by injecting s.c. 2  106 Calu-6
human lung cancer cells or 1  106 M234p murine mammary cancer
cells in nude and BALB/c mice, respectively. When the tumors
reached a median volume of approximately 600 mm3, the animals
were contralaterally challenged s.c. with 2  106 H460 human lung
cancer cells (in the case of mice bearing Calu-6 primary tumors) or
with 106 M234m murine mammary cancer cells (in the case of mice
bearing M234p primary tumors). The tumor cells used as secondary
implants are not capable of inducing CAR when used as primary
tumors (see Figures 1 and 2).–2Tumor volumes measured 20 and 17
days after contralateral s.c. inoculation of H460 and M234m, respec-
tively.–3Tumor volume inhibition was calculated as (1  E/C)  100,
where E is the median volume of secondary tumors in tumor-bearing
mice and C is that of control mice injected with tumor cells in the
second instance.–* p  0.05, ** p  0.005, Mann-Whitney U-test.
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Conversely, non-CAR-inducing H460 and M234m cells left un-
modified the plasminogen substrate, being unable to generate
angiostatin from it (Fig. 4).
Effect of proteinase inhibitors on in vitro generation of
angiostatin
CMs obtained from tumor cells that demonstrated the capacity
to convert plasminogen into angiostatin were exposed to different
enzyme inhibitors prior to their incubation with plasminogen, as
explained in Material and Methods. The angiostatin conversion
could not be abolished in either case by EDTA.Na2, discarding the
responsibility of metalloenzymes in the process (Table II). Al-
though these results were confirmed with TIMPs, some inhibitory
effect was observed with the highest doses of TIMP-1 and TIMP-2
when compared to untreated media (Fig. 5). On the other hand,
broad-spectrum serine and serine/cysteine protease inhibitors ab-
rogated angiostatin generation from plasminogen at all doses as-
sayed (Fig. 5). Inhibition of plasmin and uPA activities with
2-antiplasmin and neutralizing antibodies, respectively, sup-
pressed Calu-6 and M234p angiostatin-converting capacity in a
dose-dependent manner, but not that of M3MC, abolished by
broad-spectrum inhibitors of serine proteases (Table II). Based on
this result, the angiostatin-generating ability of M3MC could be
ascribed to one or more alternative serine proteinases that remain
to be identified.
Expression and activity of gelatinases and UPA in conditioned
media
To study the cell production of proteolytic enzymes putatively
involved in plasminogen conversion into angiostatin, we per-
formed zymographic analyses of CMs derived from cells with
angiostatin-converting capacity. While CMs from all the tumor
cells capable of inducing CAR exhibited expression of uPA, nei-
ther H460 nor M234m, which were unable to generate CAR, did
(Table III). In regard to gelatinolytic activities, only pro-MMP2
expression was observed in CMs from Calu-6, M234p and
M234m. This result demonstrates a lack of association between the
presence of this MMP and the in vitro capacity to generate an-
giostatin or the in vivo ability to induce CAR in the models used
by us. Moreover, MMP2 was found in this cell-free system as a
zymogen that, consequently, cannot digest plasminogen to gener-
ate angiostatin. Conditioned media obtained from H460 and
M3MC cell lines did not express MMPs, as demonstrated by
zymography.
DISCUSSION
The understanding of the events that drive a dormant tumor to
an invasive and then metastatic neoplasm is of fundamental im-
portance for future interventions in the therapy of cancer. Although
no definitive conclusions to explain the conversion from one stage
to the other could still be clearly drawn, many investigations
ascribe an important role to angiogenesis on this aspect. When the
delicate balance between positive and negative regulators respon-
sible for tumor dormancy is broken, whether as a consequence of
an increase in angiogenic factors, a decrease in angiogenic inhib-
itors or both, tumor progression would be triggered. On the con-
trary, an accumulation of antiangiogenic factors would result both
in formation of focal necrosis at the primary tumor and suppres-
sion of angiogenesis in metastases at distal sites.34
In many occasions, primary tumor excision gives rise to uncon-
trolled growth of metastases that might be silent in distant organs
for many years. This phenomenon, initially known as concomitant
immunity, was then found to occur with tumors of nondetectable
immunogenicity or in immunosuppressed hosts and, as a conse-
quence, we changed the word immunity for resistance, and the
concept of concomitant antitumoral resistance emerged.8 The re-
sponsibility of systemic factors that act directly on tumor cell
proliferation and/or increasing apoptosis in the generation of CAR
cannot be discarded.22,35,36 However, no experiments have been
carried out yet to demonstrate that the phenomenon can be blocked
with the use of specific inhibitors for the factors putatively in-
volved in the process. Furthermore, the finding of impaired angio-
genesis at places distant from the primary tumor in several exper-
imental models10,21,22 does not support the hypothesis of CAR
mediated by tumoristatic factors. Unless they acted by diffusion on
avascular secondary tumors, their direct delivery to tumor cells
would depend on the presence of preexisting capillaries at the site.
In this context, the finding of endogenous generation of angiostatin
and other several angiogenesis inhibitors, mainly by tumor cells,
posed the question about the relationship between their production
and the induction of CAR.
Here we extended previous studies carried out in our laboratory
in which Calu-6, a human lung carcinoma cell line showing strong
CAR, prevented neovessels from forming at places that are distant
FIGURE 3 – Antimetastatic concomitant resistance. The median
number of lung metastatic nodules generated by i.v. inoculation of
M3MC, M234p and M234m tumor cells was evaluated in mice bearing
their respective s.c. tumors () and in controls () without previous
tumor, as described in Material and Methods. The data shown repre-
sent the median values (n  6–8). p according to Mann-Whitney
U-test: *  0.01, **  0.002.
FIGURE 4 – Plasminogen conversion into angiostatin by conditioned
media (CM) of the different tumor cells. One hundred microliters of
serum-free CMs obtained from equal number of cells in all cases were
exposed to human plasminogen (2.8 g) for 48 hr at 37°C. Samples
were then subjected to nonreducing SDS-PAGE and transferred to
nitrocellulose. Detection of plasminogen conversion was evidenced by
Western blot analysis using a monoclonal antibody (1:1,000) against
kringles 1–3 domains of human plasminogen. To visualize binding of
the first antibody, a rabbit anti-mouse Fc secondary antibody conju-
gated to alkaline phosphatase (1:10,000) and nitroblue tetrazolium as
substrate were used. Purified angiostatin was used as a specific marker
(lane 1). A negative control in which plasminogen was incubated with
culture medium was also run (lane 2). Experiments were repeated at
least 3 times with essentially identical results.
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from the primary tumor, with the consequent enhancement of cell
apoptosis in secondary tumor implants.21 One more human lung
cancer cell line (H460) and 3 murine mammary cancer cells
(M3MC, M234m and M234p) were used here to investigate their
ability to induce CAR in nude and syngeneic BALB/c mice,
respectively. We observed that 3 of the 5 tumor cell types ana-
lyzed, namely Calu-6, M3MC and M234p, displayed strong CAR,
inhibiting secondary s.c. tumor implants and/or experimental lung
metastases produced by i.v. inoculations of their respective cells.
Moreover, secondary implants of other non-CAR-inducing tumor
cell types were also inhibited by CAR-inducing primary tumors.
The presence of angiostatin in sera from tumor-bearing mice
previously assayed for CAR was analyzed by Western blot after
lysine-sepharose purification. Surprisingly, despite several at-
tempts, we did not detect the antiangiogenic factor in either serum,
whereas the plasminogen found in those samples was immunode-
tected in all cases. This could be due to the absence of angiostatin
in sera or to the fact that biologically active levels of angiostatin
are below the sensitivity threshold for the technique. Recently,
other authors reported the inability to detect circulating angiostatin
in SCID mice bearing primary tumors derived from human pan-
creatic cancer cells, which also exhibited a growth-inhibitory ef-
fect on secondary tumor implants.11 Nonpublished results obtained
by us demonstrate that angiostatin can be easily detected in ascites
from cancer patients and mice, while the protein is absent or in
very low amount in their respective sera. This suggests that an-
giostatin levels are high enough to be detected by Western blot
only in those situations in which high tumor cell density is present.
As an alternative, we decided to investigate the in vitro capacity
of all tumor cells under study to convert plasminogen into an-
giostatin, even though tumor environment probably influences in
vivo production of angiostatin.37 In fact, macrophage metalloela-
stase proved to have angiostatin-converting activity.25 We found
that the ability to convert plasminogen to angiostatin in vitro was
only exhibited by those cells capable of inducing CAR. On the
other hand, conditioned media obtained from H460 and M234m
cells failed to produce proteolysis of plasminogen to generate
angiostatin.
Several proteases have been described as responsible for plasmin-
ogen conversion into angiostatin, including uPA and plasmin in the
presence of sulfhydryl donors,24 macrophage-derived metalloelastase/
MMP-12,25 matrylisin/MMP-7 and gelatinase B/MMP-9,26 plas-
min,27 stromelysin-1/MMP-3,28 gelatinase A/MMP-2,29 the serine
protease prostate-specific antigen30 and cathepsin D.31 The conver-
sion of plasminogen into angiostatin could take place in 2 steps if
plasmin acts as an intermediary molecule that functions both as
substrate and enzyme (Fig. 6a), or directly from plasminogen in 1 step
TABLE II – EFFECT OF BROAD-SPECTRUM AND SPECIFIC ENZYME INHIBITORS ON ANGIOSTATIN GENERATION
FROM PLASMINOGEN BY CONDITIONED MEDIA1
Protease inhibitor Specificity Concentration used
Angiostatin converting capacity
Calu-6 M3MC M234p
     
Aprotinin Inhibits serine proteases 100 M   
Leupeptin Inhibits serine and cysteine proteases 5 M  / 
Soybean trypsin inhibitor Inhibits trypsin and inhibits plasmin 100 g/ml   
EDTA-Na2 Inhibits metalloenzymes 5 mM   
TIMP-1 Forms complex with latent and
active MMPs, preferentially MMP-9
0.01 g/ml   
0.1 g/ml   
1 g/ml   
TIMP-2 Forms complex with latent and
active MMPs, preferentially MMP-2
0.01 g/ml   
0.1 g/ml   
1 g/ml   
2-antiplasmin Physiologic inhibitor of free plasmin
and also prevents the formation of
plasmin from plasminogen by uPA
0.01 g/ml   
0.1 g/ml   
1 g/ml   
10 g/ml   
Neutralizing anti-uPA
antibody
Neutralizes uPA activity 0.01 g/ml   
0.1 g/ml   
1 g/ml   
10 g/ml   
1The conditioned media obtained from tumor cells capable of generating angiostatin in vitro and CAR in vivo were incubated with various
proteinase inhibitors 1 hr before their exposure to plasminogen for 48 hr. Aliquots were withdrawn from the reaction mixture and analyzed by
Western blot to evidence angiostatin conversion from plasminogen or the inhibition of that process.
FIGURE 5 – Effect of broad-spectrum and specific enzyme inhibitors
on angiostatin generation from plasminogen by Calu-6 conditioned
media. The inhibitors were incubated with conditioned medium ali-
quots derived from the same number of Calu-6 cells for 1 hr at 37°C.
Human plasminogen (2.8 g) was then exposed to all the samples
(including nonconditioned culture medium and untreated Calu-6 con-
ditioned medium) for 48 hr at 37°C. Aliquots were withdrawn from the
reaction mixture and analyzed by SDS-PAGE under nonreducing
conditions and Western blot, using a monoclonal antibody to the
kringles 1–3 domains of human plasminogen. Results obtained by
preincubation of conditioned medium to highest concentration of each
of the inhibitors used are shown here. Similar effects were found for
M234p conditioned media treated with all the enzyme inhibitors
assayed, while some differences were detected for some inhibitors in
the case of M3MC (see Table II). Immunoblots in which the dose-
response effect of specific enzyme inhibitors was analyzed are shown
by representative lanes in which each highest concentration was tested.
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(Fig. 6b). In the first case, the Arg561-Val562 peptide bond in native
[Glu]-plasminogen is cleaved by uPA or tPA, yielding the 2-chain
disulfide-linked enzyme plasmin. Angiostatin results as a conse-
quence of plasmin autoproteolysis; its amino-terminal preactivation
peptide is released by hydrolysis of the Lys76-Lys77 peptide bond and
the kringle domain 4 separated from kringle domain 5 by cleavage at
Val441-Val442.24 Reduction of plasmin disulfide bonds linking heavy
and light (serine protease module) chains by free sulfhydryl donors
has also been reported.27 In the 1-step conversion process (Fig. 6b), a
cleavage between amino acid residues Lys77-Lys78 located at the
amino-terminal region of plasminogen can occur by intervention of
MMP-7,26 MMP-926 or PSA,30 between Glu59-Asn60 when MMP-3
acts,28 or between Leu74-Phe75 by action of cathepsin D.31 An addi-
tional cleavage occurs at the amino acid residues Pro446-Pro447 in the
linker region between the kringle domain 4 and kringle domain 5 by
MMP-9,26 or in the same region between Pro447-Val448 by MMP-328
or MMP-7,26 between Glu439-Ala440 by PSA action,30 or between
Leu451-Pro452 due to cathepsin D.31 The cleavage sites for other
proteinases involved in plasminogen conversion to angiostatin have
not been clearly elucidated yet.
Here we intended to define the nature of the proteases involved
in the in vitro generation of angiostatin by Calu-6, M3MC and
M234p, cells that were capable of converting plasminogen into
angiostatin, as demonstrated by Western blot. Their CMs were
incubated with different enzyme inhibitors, followed by exposure
to plasminogen and finally Western blot to detect the resulting
product. The use of EDTA.Na2 did not abolish angiostatin gener-
ation, discarding the involvement of metalloproteinases in the
process. Similar results were obtained with TIMP-1 and TIMP-2,
although the highest doses used revealed some inhibitory effect
with respect to untreated media. Conversely, preincubation of CMs
with 3 serine proteases inhibitors (one of them also an inhibitor of
cysteine proteases) abrogated angiostatin conversion from plas-
minogen. The use of 2-antiplasmin and neutralizing anti-uPA
antibody also reverted the capacity to generate angiostatin in
Calu-6 and M234p, but could not do it in M3MC. These data
indicate that, except for M3MC which seems to generate angiosta-
tin by a still not identified serine protease, other than plasmin, the
plasminogen-angiostatin-converting activity of Calu-6 and M234p
cells would mainly depend on the action of uPA and plasmin.
Furthermore, zymographic studies revealed uPA expression only
in cells that were able to generate angiostatin, while MMP-2 was
evident in 3 cases independently to their plasminogen-angiostatin-
converting capacity and only in its latent form.
Other studies, as well as the present, reveal a constantly increas-
ing list of proteolytic enzymes that are able to produce angiosta-
tin24–31 endowed with antitumoral and/or antimetastatic activity in
several experimental models.38–45 These findings put under con-
sideration not only the already known complexity of the processes
of tumor progression and metastatic growth control but also the
apparent contradictory action of some proteolytic enzymes se-
creted by tumor cells or tumor-associated host cells. These pro-
teinases can act in both supporting tumor angiogenesis, invasion
and dissemination, and inducing the generation of factors that
directly or indirectly inhibit them. Hence, certain patterns of ho-
meostatic regulation would take place in cancer, where molecules
that promote a process can also inhibit it. It is obvious that such
“regulation” is not equilibrated in cancer as in health and, there-
fore, the knowledge of this delicate and complex mechanism could
suggest new pathways for the proposal of therapies leading to
normality.
Besides, an important warning can be drawn from these con-
siderations. TIMP-2 expression, for example, not always would act
as an inhibitor of MMPs but as an enhancer of pro-MMP-2
activation.46 In the same direction, the presence of different pro-
teolytic enzymes in tumors or in serum should not necessarily be
FIGURE 6 – Potential mechanisms by which angiostatin
generation could take place. (a) In a two-step process, uPA
(or tPA) generates the 2-chain disulfide-linked enzyme plas-
min. Then, plasmin autoproteolysis gives rise to angiostatin.
(b) A one-step conversion from plasminogen to angiostatin
could be accomplished by a variety of MMPs, cathepsin D
and the kallikrein-like serine protease PSA. Peptide bond
where cleavage has been previously identified is shown in
brackets for each proteinase. Dashed lines indicate alternative
N-termini and/or C-termini in angiostatin, depending on
cleavage sites of the proteinases involved.
TABLE III – GELATINASE AND UPA EXPRESSION REVEALED BY
ZYMOGRAPHIC STUDIES OF CONDITIONED MEDIA FROM
THE DIFFERENT CANCER CELLS1
Enzyme
Enzymatic activity demonstrated in zymograms by the
different tumor cells
Calu-6 H460 M3MC M234p M234m
ProMMP-9     
MMP-9     
ProMMP-2     
MMP-2     
UPA     
1Substrate gel electrophoresis was performed on nonconcentrated
cell-number-standardized conditioned media by standard techniques.
Gelatinase or uPA activities, revealed as zones of clearance, were
indicated as positive () or negative ().
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taken as an indicator of progression. It could also suggest the
generation of angiostatic factors and the development of CAR with
the resulting halt in metastasis growth.
Our results, based in 5 different tumor models, reveal a differ-
ential in vitro production of angiostatin by CAR-inducing cancer
cells and non-CAR-inducing cancer cells. Whether this finding
should be considered the actual explanation of the phenomenon of
CAR remains to be investigated. Unfortunately, a causative rela-
tion could not be verified by us, owing to the nonexistence of
specific inhibitors of angiostatin that could help to clarify the CAR
phenomenon. Since angiostatin is an internal fragment of plasmin-
ogen, all anti-angiostatin antibodies will recognize the precursor
molecule as well as plasmin, making them useless for in vivo
blocking studies. The data obtained by us do not exclude the
possibility that, in some cases, CAR may be explained by mech-
anisms that do not rely on the production of angiostatin. For that
reason, we are now studying the presence of other angiogenic
inhibitors and inducers in different tumor models in which the
CAR capacity will be analyzed. This type of study could help to
understand the phenomenon that puzzled surgeons for so many
years, that of rapid growth of visceral metastases occurring in
many occasions after surgical resection of primary tumors.
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